<DOC>
	<DOCNO>NCT01562743</DOCNO>
	<brief_summary>The aim trial ass safety efficacy SPM 962 follow once-a-daily transdermal administration within range 2.25 6.75 mg/day Japanese patient restless legs syndrome ( RLS ) multi-center , open-label trial . The maximum treatment period 53 week . The trial extension trial precedent 6-week , double-blind , randomize , placebo-controlled , parallel-group comparative trial ( 243-07-003 ) . The trial also exploratory investigation incidence augmentation , problematic complication dopaminergic treatment .</brief_summary>
	<brief_title>A Long-Term Extension Trial From Late Phase II SPM 962 Patients With Restless Legs Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Psychomotor Agitation</mesh_term>
	<mesh_term>Restless Legs Syndrome</mesh_term>
	<mesh_term>N 0437</mesh_term>
	<criteria>Subject complete precede trial 24307003 ( NCT00666965 ) Subject discontinue precede trial 24307003 ( NCT00666965 ) Subject serious adverse event association investigational drug rule trial 24307003 Subject persistent serious adverse event baseline , observe association investigational drug rule trial 24307003 . Subject persistent hallucination delusion trial 24307003 . Subject psychiatric condition confusion , excitation , delirium , abnormal behaviour baseline . Subject orthostatic hypotension systolic blood pressure ( SBP ) ≤ 100 mmHg decrease SBP spine stand position ≥ 30 mmHg baseline . Subject history epilepsy , convulsion etc . trial 24307003 . Subject develop serious ECG abnormality baseline . Subject QTcinterval ≥ 500 msec baseline subject increase QTcinterval ≥ 60 msec baseline trial 24307003 QTcinterval &gt; 470 msec female &gt; 450 msec male baseline . Subject serum potassium level &lt; 3.5 mEq/L end taper period trial 24307003 . Subject total bilirubin ≥ 3.0 mg/dL AST ( GOT ) ALT ( GPT ) great 2.5 time upper limit reference range ( ≥ 100 IU/L ) end period trial 24307003 . Subject BUN ≥ 30 mg/dL serum creatinine ≥ 2.0 mg/dl end taper period trial 24307003 . Subject planned pregnancy trial . Subject judged inappropriate trial investigator reason .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>March 2014</verification_date>
</DOC>